Abstract:OBJECTIVE:To investigate the apoptosis and Fas (CD95) expression of T lymphocytes from the peripheral blood and peritoneal fluid of the patients with ovarian cancer and their relationship with CA125. METHODS:Apoptosis and Fas expression of peritoneal fluid and peripheral blood T lymphocytes were assessed by flow cytometry. Peripheral blood samples were obtained from the following objects respectively: patients with stage III - IV ovarian cancer (n = 18) before and after treatment, patients with stage I - II ovarian cancer (n = 15), patients with benign ovarian tumor (n = 18), patients with Krukenberg tumor (n = 6) and normal control (n = 20). Peritoneal fluids were obtained from all the patients with ovarian cancer, Krukenberg tumor and ten patients with benign ovarian tumor. Level of serum CA125 of the patients with ovarian cancer was assessed. RESULTS:In the patients with stage III - IV ovarian cancer, the apoptosis level of the peripheral blood T lymphocytes was 5.55 (3.57 - 9.62)%, significantly higher than those from the patients with stage I - II ovarian cancer, patients with benign ovarian tumor, controls (P < 0.008 in all instances) and the patients with stage III - IV ovarian cancer after treatment (P < 0.05). The intensity of Fas expression of the peripheral blood T lymphocytes from the patients with stage III - IV ovarian cancer was 51 +/- 10, significantly higher than that from controls (P < 0.05). In peritoneal fluid, the apoptosis rates of T lymphocytes, positive rate and intensity of Fas expression on T lymphocytes from patients with stage I - II and stage III - IV ovarian cancer were 17.41 (7.06 - 24.56)%, (57 +/- 16)%, (55 +/- 11)% and 34.06 (17.03 - 44.65)%, (66 +/- 12)%, (70 +/- 24)%, respectively, increased significantly compared with those from patients with benign ovarian tumor, which were 0.78 (0.67 - 1.44)%, (37 +/- 6)%, 43 +/- 6, respectively (P < 0.01 in all instances). The apoptosis level and positive rate of Fas expression on peritoneal fluid T lymphocytes from patients with stage III - IV ovarian cancer were significantly higher than those from patients with Krukenberg tumor (P < 0.01). There was a positive correlation between the serum CA125 level and the apoptosis level of peritoneal fluid T cell in the patients with stage I - II ovarian cancer (r = 0.77, P = 0.009). For ovarian cancer, the apoptosis level of peritoneal fluid T lymphocytes from patients with the serum CA125 > 500 KU/L was higher than that from the patients with the serum CA125 < or = 500 KU/L (P = 0.009). CONCLUSIONS:(1) Extraordinarily increased apoptosis of T cells may play an important role in the development of systemic and celiac immunodeficiency in the patients with ovarian cancer. In contrast with the patients with Krukenberg tumor, the patients with advanced ovarian cancer hare higher percentage of apoptotic peritoneal fluid T lymphocytes, which shows the particularity of local immunity defect. (2) For the patients with ovarian cancer, efficient treatment can decrease the percentage of apoptotic peripheral blood T lymphocytes. (3) The increased positive rate and intensity of Fas expression on peritoneal fluid T lymphocytes stressed the significance of Fas interference in the treatment of ovarian cancer. (4) Level of serum CA125 can reflect the celiac immunity defection in patients with ovarian cancer.

OVER-EXPRESSION OF C-FLIP AND BCL-2 RESULTS IN THE RESISTANCE TO TRAIL-INDUCED APOPTOSIS ON OVARIAN CANCER

Molecular Mechanisms of Resistance to TRAIL-induced Apoptosis in Tumor

Overcoming acquired resistance to TRAIL by chemotherapeutic agents and calpain inhibitor I through distinct mechanisms.

Bcl-XL Sirna Sensitizes Ovary Cancer Cells in TRAIL-induced Apoptosis

Relationship between c-FLIP protein and drug resistance of ovarian cancer cells to TRAIL-induced apoptosis

Overcoming acquired resistance to tumor necrosis factor-related apoptosis-inducing ligand by Bcl-XL small interfering RNA in human colon cancer

Overcoming Acquired TRAIL Resistance in Human Colon Cancer by Proteasome Inhibitor Bortezomib

Over-expression of c-FLIP confers the resistance to TRAIL-induced apoptosis on gallbladder carcinoma.

Changes and Significance of Fas and Cflip in Apoptosis of Human Rhabdomyosarcoma Cells Induced by Combination of TRAIL and Cisplatin

Promotion of TRAIL-induced Apoptosis by Sirna to FLIP Gene in Ovarian Cancer Cell Line A2780

Induction of Apoptosis by TNF-related Apoptosis-Inducing Ligand in Human Ovarian Cancer Cells

Persistent C-Flip(l) Expression is Necessary and Sufficient to Maintain Resistance to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Mediated Apoptosis in Prostate Cancer.

Down-regulation of intracellular anti-apoptotic proteins, particularly c-FLIP by therapeutic agents; the novel view to overcome resistance to TRAIL

Pro-survival Effects by NF-κB, Akt and ERK(1/2) and Anti-Apoptosis Actions by Six1 Disrupt Apoptotic Functions of TRAIL-Dr4/5 Pathway in Ovarian Cancer

C-Flip Degradation Mediates Sensitization of Pancreatic Cancer Cells to TRAIL-induced Apoptosis by the Histone Deacetylase Inhibitor LBH589.

Experimental Study on Apoptosis in T Cells Induced by Ovarian Carcinoma Cells

Enhancing TRAIL-induced apoptosis by Bcl-XL siRNA

Study of Apoptosis and Fas Expression of Peritoneal Fluid and Peripheral Blood T Lymphocytes in Patients with Epithelial Ovarian Cancer and Their Relationship with CA125

C-Fos As A Proapoptotic Agent in Trail-Induced Apoptosis in Prostate Cancer Cells

The Expression of TRAIL, TRAIL-R(DR4,DcR1) and Fas-L in Patients with Ovarian Cancer

Prognostic significance of TRAIL signalling molecules in cervical squamous cell carcinoma